No abstract

Treatment for 12 months with BAK-free travoprost after BAK-preserved latanoprost resulted in fewer ocular surface complications, as indicated by the reduced prevalence of SPK and decreased hyperemia, and no clinically relevant changes in IOP. BAK-free travoprost may have beneficial effects on the ocular surface while showing IOP-lowering efficacy comparable with BAK-preserved eye drops.

No abstract

We used a theoretical eye model to evaluate the effect on peripheral images when planoconvex, biconvex, and meniscus intraocular lenses (IOLs) decenter 1 mm or 2 mm upward or downward from the pupillary center. A light source was projected from an angle of 0, 20, 28, or 40 degrees downward to a retina with a radius of curvature of 11 mm. When the IOL was centered, the light focused at a single point on the retina. When the IOL was decentered, the light became more dispersed as the incident angle of the light increased. The most dispersion was noted with the meniscus IOL; the least with the biconvex IOL. Astigmatism and aberration, which IOL decentration increases, were thought to cause the image defocus. These results suggest that IOL decentration may affect the sharpness of peripheral images.

PurposeTo evaluate the efficacy and safety of brinzolamide 1%/timolol 0.5% fixed-combination (BRINZ/TIM-FC) therapy compared with timolol 0.5% (TIM) monotherapy in Japanese patients with open-angle glaucoma or ocular hypertension.MethodsThis randomized, double-masked, multicenter study included Japanese patients aged ≥20 years. Patients were treated during a 4-week observation period with TIM monotherapy in advance of randomization to treatment with topical BRINZ/TIM-FC or TIM monotherapy twice daily for 8 weeks. The primary endpoint was mean reduction in intraocular pressure (IOP) from baseline to week 8 at 2 hours postinstillation. Adverse events (AEs) were recorded at each visit.ResultsA total of 301 patients (BRINZ/TIM-FC, n=150; TIM, n=151; age [mean ± standard deviation], 61±13 years) were enrolled. Mean IOP reductions from baseline were greater with BRINZ/TIM-FC than with TIM at weeks 4 and 8 at 0 and 2 hours postinstillation (all P≤0.0001), with mean reductions of −3.2 mmHg with BRINZ/TIM-FC and −1.4 mmHg with TIM at week 8, 2 hours postinstillation. Although AEs were observed in 19% of all patients (BRINZ/TIM-FC, 20%; TIM, 19%), all AEs were mild or moderate.ConclusionBRINZ/TIM-FC therapy was associated with significantly greater reductions in IOP compared with TIM, and it was well tolerated in Japanese patients with open-angle glaucoma or ocular hypertension.